Literature DB >> 26026861

Adult medulloblastoma: clinical characters, prognostic factors, outcomes and patterns of relapse.

Na Zhang1, Taohui Ouyang2, Huicong Kang1, Wang Long2, Benjamin Thomas3, Suiqiang Zhu4.   

Abstract

To analyze the clinical characters, prognostic factors, patterns of relapse and treatment outcomes for medulloblastoma in adults. The clinical materials of 73 consecutive adult patients (age, ≥16 years) with medulloblastoma were analyzed retrospectively. Follow-up data were available in 62 patients, ranging from 10 to 142 months (median, 78.4 months). Outcome in survival was assessed by the progression-free survival (PFS) and overall survival (OS). Univariate and multivariate analysis were performed to determine the prognostic factors. Total or near-total tumor resection was achieved in 37 cases (59.7 %), subtotal in 19 cases (30.6 %), and partial resection in 6 cases (9.7 %).Twenty-two patients experienced recurrences, and 45 % percent of all recurrences occurred more than 4 years after initial surgery. The PFS rates at 5 and 8 years were 60.1 and 37.0 %, respectively. The OS rates at 5 and 8 years were 82.6 and 57.3 %, respectively. In univariate analysis, less tumor resection, non-desmoplastic pathology, and brainstem involvement were risk factors for worse PFS and OS (P < 0.05). High-risk category was associated with just lower PFS, but not OS. In multivariate analysis, complete resection and desmoplastic pathology were independently predictive factors of improved PFS and OS. In adult medulloblastoma, late relapse is common and therefore long-term follow-up is important for evaluating the real impact of treatments. Risk category had prognostic value just for PFS, but not for OS. Complete resection and desmoplastic histology are independently predictive factors for favorable outcomes.

Entities:  

Keywords:  Adult; Chemotherapy; Medulloblastoma; Posterior fossa

Mesh:

Year:  2015        PMID: 26026861     DOI: 10.1007/s11060-015-1833-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  43 in total

1.  Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children.

Authors:  Jacques Grill; Christian Sainte-Rose; Anne Jouvet; Jean-Claude Gentet; Odile Lejars; Didier Frappaz; François Doz; Xavier Rialland; Fabienne Pichon; Anne-Isabelle Bertozzi; Pascal Chastagner; Dominique Couanet; Jean-Louis Habrand; Marie-Anne Raquin; Marie-Cécile Le Deley; Chantal Kalifa
Journal:  Lancet Oncol       Date:  2005-08       Impact factor: 41.316

2.  Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study.

Authors:  P M Zeltzer; J M Boyett; J L Finlay; A L Albright; L B Rorke; J M Milstein; J C Allen; K R Stevens; P Stanley; H Li; J H Wisoff; J R Geyer; P McGuire-Cullen; J A Stehbens; S B Shurin; R J Packer
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

Review 3.  Medulloblastomas in adults: prognostic factors and lessons from paediatrics.

Authors:  Cristina Nay Fellay; Didier Frappaz; Marie P Sunyach; Enrico Franceschi; Alba A Brandes; Roger Stupp
Journal:  Curr Opin Neurol       Date:  2011-12       Impact factor: 5.710

4.  Epidemiology of adult medulloblastoma.

Authors:  M T Giordana; P Schiffer; M Lanotte; P Girardi; A Chio
Journal:  Int J Cancer       Date:  1999-03-01       Impact factor: 7.396

5.  Survival and prognostic factors in a series of adults with medulloblastomas.

Authors:  Laurent Riffaud; Stephan Saikali; Emmanuelle Leray; Abderrahmane Hamlat; Claire Haegelen; Elodie Vauleon; Thierry Lesimple
Journal:  J Neurosurg       Date:  2009-09       Impact factor: 5.115

6.  Medulloblastoma in children under the age of three years: a retrospective Canadian review.

Authors:  Donna L Johnston; Daniel Keene; Ute Bartels; Anne-Sophie Carret; Bruce Crooks; David D Eisenstat; Chris Fryer; Lucie Lafay-Cousin; Valerie Larouche; Albert Moghrabi; Beverly Wilson; Shayna Zelcer; Mariana Silva; Josee Brossard; Eric Bouffet
Journal:  J Neurooncol       Date:  2009-01-31       Impact factor: 4.130

7.  Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression.

Authors:  Talitha de Haas; Nancy Hasselt; Dirk Troost; Huib Caron; Mara Popovic; Lorna Zadravec-Zaletel; Wieslawa Grajkowska; Marta Perek; Maria-Chiara Osterheld; David Ellison; Frank Baas; Rogier Versteeg; Marcel Kool
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

8.  Medulloblastoma: time-dose relationship based on a 30-year review.

Authors:  J O del Charco; T W Bolek; W M McCollough; B L Maria; A Kedar; R C Braylan; J P Mickle; J M Buatti; N P Mendenhall; R B Marcus
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-08-01       Impact factor: 7.038

9.  Medulloblastoma in adults.

Authors:  M D Prados; R E Warnick; W M Wara; D A Larson; K Lamborn; C B Wilson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-07-15       Impact factor: 7.038

10.  The treatment of adults with medulloblastoma: a prospective study.

Authors:  Alba A Brandes; Mario Ermani; Pietro Amista; Umberto Basso; Francesca Vastola; Marina Gardiman; Paolo Iuzzolino; Sergio Turazzi; Antonino Rotilio; Lorenzo Volpin; Carlo Mazza; Laura Sainati; Franco Ammannati; Franco Berti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-11-01       Impact factor: 7.038

View more
  9 in total

Review 1.  The clinical importance of medulloblastoma extent of resection: a systematic review.

Authors:  Eric M Thompson; Alexa Bramall; James E Herndon; Michael D Taylor; Vijay Ramaswamy
Journal:  J Neurooncol       Date:  2018-05-23       Impact factor: 4.130

2.  Medulloblastoma in adults : A retrospective single institution analysis.

Authors:  Indrawati Hadi; Olarn Roengvoraphoj; Maximilian Niyazi; Falk Roeder; Ulrich Schüller; Claus Belka; Silke Birgit Nachbichler
Journal:  Strahlenther Onkol       Date:  2017-11-16       Impact factor: 3.621

3.  Medulloblastoma with soft-tissue and skeletal metastases in an adult: A case report.

Authors:  Dianzhong Geng; Xiaohua Song; Jing Liu; Zeshun Yu; Fangling Ning
Journal:  Oncol Lett       Date:  2015-08-11       Impact factor: 2.967

4.  Never Too Old? Occurrence of Medulloblastoma in the Elderly beyond the 70th Year of Life.

Authors:  Homajoun Maslehaty; Johannes Van de Nes; Sarah Teuber-Hanselmann; Christoph Moenninghoff; Ulrich Sure; Neriman Oezkan
Journal:  Case Rep Neurol Med       Date:  2018-06-07

Review 5.  Adult Medulloblastoma: Updates on Current Management and Future Perspectives.

Authors:  Enrico Franceschi; Caterina Giannini; Julia Furtner; Kristian W Pajtler; Sofia Asioli; Raphael Guzman; Clemens Seidel; Lidia Gatto; Peter Hau
Journal:  Cancers (Basel)       Date:  2022-07-29       Impact factor: 6.575

6.  Outcomes and patterns of care in a nationwide cohort of pediatric medulloblastoma: Factors affecting proton therapy utilization.

Authors:  Andrew S Kopecky; Atif J Khan; Wilbur Pan; Richard Drachtman; Rahul R Parikh
Journal:  Adv Radiat Oncol       Date:  2017-07-19

7.  Radiotherapy for Adult Medulloblastoma: Evaluation of Helical Tomotherapy, Volumetric Intensity Modulated Arc Therapy, and Three-Dimensional Conformal Radiotherapy and the Results of Helical Tomotherapy Therapy.

Authors:  Sun Zong-Wen; Yang Shuang-Yan; Du Feng-Lei; Cheng Xiao-Long; Li Qinglin; Chen Meng-Yuan; Hua Yong-Hong; Jin Ting; Hu Qiao-Ying; Chen Xiao-Zhong; Chen Yuan-Yuan; Chen Ming
Journal:  Biomed Res Int       Date:  2018-03-21       Impact factor: 3.411

8.  Adult-onset medulloblastoma presenting as slow-growing, atypical mass: a case report.

Authors:  Anja Gwendolyn van der Kolk; Roeland B van Leeuwen; Louise Poulsen
Journal:  BJR Case Rep       Date:  2017-01-25

Review 9.  Pediatric versus Adult Medulloblastoma: Towards a Definition That Goes beyond Age.

Authors:  Joseph R Wooley; Marta Penas-Prado
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.